Researchers at the University of Arkansas will try to make a vaccine to prevent recurrence of breast cancer in the next few months. If successful, this vaccine will not replace the role of therapies such as chemotherapy and radiation, but can be a form of adjunctive therapy for the patient, mentioned by Laura Hutchins, chairman of the study, professor of hematology and oncology section. Thomas Kieber-Emmons, director of basic breast cancer research at the UAMS Winthrop P. Rockefeller Cancer Institutes, said that the vaccine has been developed since the last decade. He said the key is understanding how molecules can work together to fight the disease.
Breast cancer cells surrounded by molecules called antigens. These antigens can trigger the production of antibodies that can fight cancer cells. But the carbohydrate antigens of cancer cells is not strong enough to stimulate an immune response. Kieber-Emmons and his team tried to create alternatives to develop antigen-like carbohydrates. Peptides are the components that contain two or more amino acids. Peptides in the vaccine stimulates the body to release antibodies directed to both peptides and carbohydrates that they develop in the breast cancer cells.
This experiment consists of several phases. The first phase will last for 4-6 months and involving women with breast cancer that spreads very active, and Wanta with breast cancer who re-emerged after a remission. These women will receive 5 doses of vaccine. The second phase will last about a year and involve women who have had breast cancer but who are currently in a state of remission as well as having a high risk to recur. The woman should at least stop the chemotherapy for 6 months. Number of subjects of this study could not be determined.
Breast cancer is one of the biggest causes of death in Hispanic women as well as the number 2 killer of white women, black, Asian, and American Indians. In 2004, 40 954 women died of breast cancer, according to recent data the Centers for Disease Controls
Breast cancer cells surrounded by molecules called antigens. These antigens can trigger the production of antibodies that can fight cancer cells. But the carbohydrate antigens of cancer cells is not strong enough to stimulate an immune response. Kieber-Emmons and his team tried to create alternatives to develop antigen-like carbohydrates. Peptides are the components that contain two or more amino acids. Peptides in the vaccine stimulates the body to release antibodies directed to both peptides and carbohydrates that they develop in the breast cancer cells.
This experiment consists of several phases. The first phase will last for 4-6 months and involving women with breast cancer that spreads very active, and Wanta with breast cancer who re-emerged after a remission. These women will receive 5 doses of vaccine. The second phase will last about a year and involve women who have had breast cancer but who are currently in a state of remission as well as having a high risk to recur. The woman should at least stop the chemotherapy for 6 months. Number of subjects of this study could not be determined.
Breast cancer is one of the biggest causes of death in Hispanic women as well as the number 2 killer of white women, black, Asian, and American Indians. In 2004, 40 954 women died of breast cancer, according to recent data the Centers for Disease Controls
No comments:
Post a Comment